Multiple sclerosis: A paradigm change with oral agents?

Formulary

Volumn 46, Issue 6, 2011, Pages 228-240

  Tam, Selina ^a   Lopez, Amber ^b   Shek, Allen ^b   Yeh, Johnathan ^c  

^a Health Plan of San Joaquin ^*  (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c Health Plan of San Joaquin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; ESTRADIOL; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GESTAGEN; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; LIVER ENZYME; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; NEW DRUG; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ABDOMINAL PAIN; ADD ON THERAPY; ALLERGY; ALOPECIA; ANTIBODY PRODUCTION; ANXIETY; ARTHRALGIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; BACKACHE; BALANCE DISORDER; BRADYCARDIA; BREAST CANCER; CARDIOTOXICITY; CHRONIC DISEASE; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DEPRESSION; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; HEADACHE; HEART PALPITATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIFE EXPECTANCY; LIPOATROPHY; LYMPHOCYTOPENIA; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; SEIZURE; SIDE EFFECT; SKIN CANCER; SUICIDAL IDEATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS ENCEPHALITIS; VIRUS INFECTION; VOMITING; WALKING SPEED;

EID: 81155154200     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. National Multiple Sclerosis Society. About MS: Who Gets MS? http://nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx. Accessed January 31, 2011.
2. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull. 2010;95:79-104.
3. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-1702.
4. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606-616.
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
6. Spain RI, Cameron MH, Bourdette D. Recent developments in multiple sclerosis therapeutics. BMC Med. 2009;7:74.
7. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. http://www.nationalmssociety.org/download.aspx?id=8. Accessed January 31, 2011.
8. Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2008.
9. Rebif [package insert]. Rockland, ME: EMD Serono, Inc.; New York, NY: Pflzer, Inc.; 2009.
10. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010.
11. Copaxone [package insert]. Kansas City, MO: Teva Neuroscience, Inc.; 2009.
12. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
13. Ampyra [package insert]. Hawthorne, NY: Acorda Therapeuticals, Inc.; 2010.
14. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. AHRQ, National Guideline Clearinghouse, NGC-3144. http://www.guideline.gov/content.aspx?id=4099&search=multiple+sclerosis. Accessed August 10, 2010.
15. Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg. 2010;112:365-385.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. And the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
17. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
18. Johnson KP. Risks vs beneflts of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag. 2010;6:153-172.
19. Johnson KP, Brooks BR, Cohen JA, et al. And the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268-1276.
20. Gawronski KM, Rainka MM, Patel MJ, Gengo FM. Treatment options for multiple sclerosis: current and emerging therapies. Pharmacotherapy. 2010;30:916-927.
21. Panitch H, Goodin DS, Francis G, et al. For the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon ß-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59:1496-1506.
22. Durelli L, Verdun E, Barbero P, et al. And the Independent Comparison of Interferon (IN-COMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453-1460.
23. O'Connor P, Filippi M, Arnason B, et al. For the BEYOND Study Group. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889-897.
24. Mikol DD, Barkhof F, Chang P, et al. On behalf of the REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-914.
25. Cadavid D, Wolansky LJ, Skurnick J, et al. Efflcacy of treatment of MS with IFNß-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72:1976-1983.
26. Hartung H, Gonsette R, König N, et al. And the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018-2025.
27. Polman CH, O'Connor PW, Havrdova E, et al. For the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
28. Rudick RA, Stuart WH, Calabresi PA, et al. For the SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-923.
29. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117:77-93.
30. Kappos L, Radue EW, O'Connor P, et al.For the FREEDOMS Study Group. A placebo-controlled trial of oral flngolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
31. Cohen JA, Barkhof F, Comi G, et al. For the TRANSFORMS Study Group. Oral flngolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.
32. http://www.clinicaltrials.gov. Accessed March 2, 2011.
33. Hauser SL, Johnston SC. 4-Aminopyri-dine: new life for an old drug. Ann Neurol. 2010;68:A8-A9.
34. Goodman AD, Brown TR, Edwards KR, et al. On behalf of the MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68:494-502.
35. Goodman AD, Brown TR, Krupp LB, et al. On behalf of the Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732-738.
36. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13:245-261.
37. Goldberg LD, Edwards NC, Fincher C, Doan QU, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the flrst-line treatment of relapsingremitting multiple sclerosis. J Manag Care Pharm. 2009;15:543-555.
38. Fox EJ. Emerging oral agents for multiple sclerosis. Am J Manag Care. 2010;16:S219-S226.
39. Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2010;10:381-388.
40. Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, infiammatory demyelination and acute axonal damage in mice with experimentalautoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133-143.
41. Comi G, Pulizzi A, Rovaris M, et al. For the LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-2092.
42. Warnke C, Meyer Zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Review of terifiunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333-340.
43. O'Connor PW, Li D, Freedman MS, et al. On behalf of the Terifiunomide Multiple Sclerosis Trial Group and the University of British Columbia MS/ MRI Research Group. A phase II study of the safety and efflcacy of terifiunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
44. Bista P, Ryan S, Hahm K, et al. Dimethyl fumarate (BG00012) inhibits astrocyte and microglial activation. Multiple Sclerosis. 2009;15:S132.
45. Kappos L, Gold R, Miller DH, et al. For the BG-12 Phase IIb Study Investigators. Efflcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463-1472.
46. Giovannoni G, Comi G, Cook S, et al. For the CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
47. Gandey A. Medscape website. http://www.med-scape.com/viewarticle/738239. Updated March 2, 2011. Accessed March 2, 2011.